Fig. 2From: Are there socio-economic inequalities in utilization of predictive biomarker tests and biological and precision therapies for cancer? A systematic review and meta-analysisForest plot showing predictive biomarker test utilization odds (sub-grouped by cancer type) for low compared to high socio-economic status. ALK, anaplastic lymphoma kinase; BRAF, proto-oncogene B-Raf; HER2, human epidermal growth factor receptor 2; KRAS, oncogene KRAS; SES, socio-economic statusBack to article page